A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Status:
Recruiting
Trial end date:
2032-08-01
Target enrollment:
Participant gender:
Summary
Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast
cancer, especially triple-negative breast cancer(TNBC). Our trial aims to improve the outcome
of TNBC patients by using ctDNA to identify patients with high relapse risk. ctDNA positive
patients will be randomized to receive boost therapy or standard therapy indicated in NCCN
guidelines after NAC.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University